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ABSTRACT
Objectives To develop a new methodology to
systematically compare evidence across diverse risk
markers for coronary heart disease and to compare this
evidence with guideline recommendations.
Design “Horizontal” systematic review incorporating
different sources of evidence.
Data sources Electronic search of Medline and hand
search of guidelines.
Study selection Two reviewers independently determined
eligibility of studies across three sources of evidence
(observational studies, genetic association studies, and
randomised controlled trials) related to four risk markers:
depression, exercise, C reactive protein, and type 2
diabetes.
Data extraction For each risk marker, the largest meta-
analyses of observational studies and genetic
association studies, and meta-analyses or individual
randomised controlled trials were analysed.
ResultsMeta-analyses of observational studies reported
adjusted relative risks of coronary heart disease for
depression of 1.9 (95% confidence interval 1.5 to 2.4), for
top compared with bottom fourths of exercise 0.7 (0.5 to
1.0), for top compared with bottom thirds of C reactive
protein 1.6 (1.5 to 1.7), and for diabetes in women 3.0
(2.4 to 3.7) and inmen 2.0 (1.8 to 2.3). Prespecified study
limitations were more common for depression and
exercise. Meta-analyses of studies that allowed formal
Mendelian randomisation were identified for C reactive
protein (and did not support a causal effect), and were
lacking for exercise, diabetes, and depression.
Randomised controlled trials were not available for
depression, exercise, or C reactive protein in relation to
incidence of coronary heart disease, but trials in patients
with diabetes showed some preventive effect of glucose
control on risk of coronary heart disease. None of the four
randomised controlled trials of treating depression in
patients with coronary heart disease reduced the risk of
further coronary events. Comparisons of this horizontal
evidence review with two guidelines published in 2007
showed inconsistencies, with depression prioritised
more in the guidelines than in our review.
Conclusions This horizontal systematic review pinpoints
deficiencies and strengths in the evidence for depression,
exercise, C reactive protein, and diabetes as
unconfounded and unbiased causes of coronary heart
disease. This new method could be used to develop a
field synopsis and prioritise future development of
guidelines and research.
INTRODUCTION
Clinical guidelines for the prevention of coronary
heart disease are important not only because they influ-
ence practice but also because they present a highly
cited collation of evidence for a multitude of risk
markers.1 2 For example, the European primary pre-
vention guidelines published in 20031 mentioned
more than 40 risk markers and have been cited more
than 800 times.
A fundamental problem in developing rational clin-
ical guidelines has been the lack of explicit, systematic
comparisons of the strength of causal evidence across
the diverse range of risk markers, which compete for
clinical attention. Traditional vertical systematic
reviews, which focus on one risk marker or a relatively
homogeneous group of related risk markers, are an
important influence on the development of clinical
guidelines. However, individual risk markers may be
championed by different experts, with few attempts at
harmonising, displaying, and comparing the evidence
across different markers. This may contribute to an ad
hoc selection not based on strength of causal evidence,
of which risk markers beyond smoking, blood pres-
sure, and cholesterol concentration are included in
guidelines. The European guidelines,1 for example,
did not consider atrial fibrillation, unlike the
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contemporaneous American guidelines.2 The large3
and expanding array of risk markers underscores the
importance of this problem, particularly sincemany of
the markers are of uncertain causal relevance and few
yet provide targets for prevention of disease.
We developed a newmethodology of horizontal sys-
tematic review to assess causal relevance across a range
of risk markers. We provide a high level overview of
synthesised evidence, based on explicit criteria of
biases and causal relevance. To show the potential of
this approachwe focused on four riskmarkers: depres-
sion, exercise, C reactive protein, and diabetes. We
selected these four markers because they differ in sev-
eral respects, including conceptual domain (psycho-
social marker, behavioural marker, circulating
biomarker, defined metabolic disease), measurement
properties (presence or absence of standard instru-
ments and internationally agreed definitions), and
whether exposure was endogenous (proximal in the
putative causal pathway) or exogenous (more distal).
We purposively selected one risk marker—diabetes—
widely accepted as having an established causal role, as
well as three markers where the causal role is not uni-
versally accepted. We hypothesised that concordance
of research evidence from differing research designs
each with different sources of error provides the stron-
gest evidence on the causal relevance of a putative risk
factor.4 Specifically, we sought evidence from three
major study designs that offer different approaches to
tackling confounding and reverse causation: tradi-
tional prospective observational studies with multi-
variate adjustments, studies that use genetic variants
as instruments to tackle confounding (so calledMende-
lian randomisation),5 6 and randomised controlled
trials where exposure to the risk marker is experimen-
tally manipulated. Finally, in the light of the horizontal
comparisonwe compared the recommendationsmade
for these four riskmarkers in themost recent guidelines
on prevention of coronary heart disease.
METHODS
The horizontal systematic review assesses causal rele-
vance across a range of riskmarkers and study designs.
We set out a priori eligibility criteria for studies, sys-
tematically obtained the studies, and extracted and dis-
played the data. Firstly, we separated information on
risk markers for first coronary heart disease events in
people initially free from clinical disease and prognos-
tic factors in patients with existing coronary heart
disease because of the clinical importance of distin-
guishing between primary and secondary prevention.
Secondly, where more than one systematic review was
identified we displayed the largest meta-analysis or
study (which tended to be better quality according to
the MOOSE,7 and QUORUM8 statements) in the
tables of main results and included details of the others
in the web extra appendix. Thirdly, we agreed a priori
that if we could find no systematic review for any ran-
domised controlled trials of the risk marker then we
would review the largest individual study. Fourthly,
we stratified data extraction and synthesis by study
design (observational studies, genetic association stu-
dies, and randomised controlled trials), but analysed
horizontally.
Observational studies
In January 2008we searchedMedline to identifymeta-
analyses of observational studies in healthy popula-
tions (aetiologic) and among patients with existing cor-
onary disease (prognostic), and contacted experts.
Existing coronary disease included patients with myo-
cardial infarction or those undergoing coronary revas-
cularisation or coronary angiography. Search terms
included the expanded medical subject heading
(MESH) of cardiovascular disease, meta-analysis as a
MESH topic or publication type, and then the four
individual risk markers as either the MESH term or
text words. English and non-English language publica-
tions were eligible. Eligible outcomes were fatal coron-
ary heart disease and non-fatal myocardial infarction
(aetiologic and prognostic studies) and, for prognostic
studies only, all cause mortality. Meta-analyses were
only eligible for inclusion if they reported summary
estimates based on longitudinal studies.
Two reviewers (HK and AAS) extracted data, with
recourse to a third reviewer in the event of disagree-
ment. We extracted summary data on prespecified
items: age adjusted (or unadjusted) relative risks with
95% confidence intervals; adjusted relative risks with
95% confidence intervals; number of studies adjusting
for smoking, blood pressure, and cholesterol concen-
tration (aetiologic) or disease severity (prognostic);
attenuation between age and multivariate adjusted
relative risks; the prevalence of exposure in individual
studies; the methods used to measure exposure; the
number and type of outcomes; the level of meta-analy-
sis (literature only, or pooled analysis of individual par-
ticipant data across the studies); measure of
heterogeneity; whether separate estimates were
reported among people aged over 75 years, women,
or non-Western populations; evidence of the presence
of a dose-response relation—that is, extending beyond
dichotomous comparisons; the extent to which the
duration of follow-up influenced the strength of the
estimates (if effects are stronger with shorter periods
of follow-up this is consistent with reverse causality);
and evidence of publication bias.
Genetic studies
We searched for meta-analyses of the associations
between genotype and each of the four individual risk
markers through Medline using gene as the MESH
term or text words or Mendelian in any field; meta-
analysis as a MESH topic or publication type; and
then the four individual risk markers as either the
MESH term or text words. To identify meta-analyses
of the association between genotype and coronary
heart disease outcome we searched individual single
nucleotide polymorphisms in all fields identified
from recent systematic reviews for depression
(SLC6A4, MTHFR, APOEw1), the CRP gene,w2 and
type 2 diabetes (TCF7L2, FTO, CDKN2A/
RESEARCH
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CDKN2B, PPARG, ICF2BP2, KCNJ11, HHEXIDE,
CDKAL1, SLC30A8w3) together with expanded
MESH headings of cardiovascular disease and meta-
analysis as a MESH topic or publication type. For
each variant two independent reviewers (HH and
AN) extracted information on prespecified items:
whether the single nucleotide polymorphismwas iden-
tified fromgenomewide scans, the number of outcome
events, the number of studies in the meta-analysis,
unadjusted relative risks (95% confidence intervals),
and whether there was a formal test on the use of the
genetic variant as an instrumental variable.6
Randomised trials
Randomised controlled trials and meta-analyses of
these were identified through searches of Medline.
Search terms included theMESH heading of coronary
heart disease or CHD or myocardial infarction or MI;
trial as a MESH heading; the four individual risk mar-
kers as either theMESH term or text words; andmeta-
analysis or systematic review as a MESH heading or
review as a publication type. Given the importance of
evidence from randomised controlled trials to inform
guidelines, we accepted individual trials where no
meta-analyses were available. We also searched
through the reference list from the guideline publica-
tions to identify relevant randomised controlled trials.
Only randomised controlled trials that reported coron-
ary heart disease event outcomes were eligible (aetio-
logic and prognostic studies) or death in the setting of
patients with coronary heart disease (prognostic stu-
dies). Two independent reviewers (HK and AAS)
extracted details on the nature of the intervention, the
number of studies in the meta-analysis, the number
and type of end points, the relative risk (95% confi-
dence interval) of coronary heart disease or death,
and whether the intervention had an effect on the risk
marker.
Selection of guidelines
Tomake contemporaneous comparisons with our evi-
dence reviewwe included guidelines only published in
2007 as this was the most recent information available
to us. We identified two guidelines, which were devel-
oped through independent processes, from the Scot-
tish Intercollegiate Guideline Network9 and the
fourth Joint European Societies10 11 (coordinated by
the European Society of Cardiology, and representing
nine professional organisations).Across each guideline
and risk marker we compared the evidence cited,
description of the causal relevance of the marker,
recommendations onmeasurement in healthy popula-
tion settings, inclusion in risk scores, recommenda-
tions for specific interventions, and target levels or
goals for risk marker levels.
RESULTS
The figure shows the results of the meta-analyses of
observational studies, genetic variants, and rando-
mised controlled trials for depression, exercise, C reac-
tive protein, and diabetes in relation to risk of coronary
heart disease. These riskmarkers differed noticeably in
the type and amount of evidence identified.
Observational studies
Table 1 summarises the largest meta-analyses found
for each of the risk markers. Meta-analyses of observa-
tional studies reported adjusted aetiologic relative risks
of coronary heart disease for depression of 1.9 (95%
confidence interval 1.5 to 2.4; 1262 events in 11 stu-
dies), for top compared with bottom fourth of exercise
of 0.7 (0.5 to 1.0; 500 events in three studies), for top
compared with bottom third of C reactive protein of
1.6 (1.5 to 1.7; 7068 events in 22 studies), and for dia-
betes in women of 3.0 (2.4 to 3.7) and inmen of 2.0 (1.8
to 2.3; >4964 events in 29 studies). Meta-analyses of
the association in patients with coronary heart disease
(prognostic studies) reported an adjusted relative risk
of further coronary heart disease events or death for
depression of 1.6 (1.3 to 1.9; >525 events in 11 studies)
and an adjusted relative risk of cardiac death for dia-
betes of 1.5 (1.1 to 2.0; 240 events in four studies). No
prognostic meta-analyses were identified for the effect
of exercise or C reactive protein on outcome among
patients with coronary heart disease. A dose-response
effect was reported for intensity of physical activity but
not consistently for major depression compared with
minor depression, concentration of C reactive protein,
or glucose control in people with diabetes. None of the
meta-analyses reported effects separately among those
older than 75 years (or other age groups of older peo-
ple), and only for diabetes was there evidence of con-
sistent effects in non-Western populations. Effect
estimates for C reactive protein and diabetes were pre-
sented separately for men and women, with observa-
tional evidence for diabetes showing a stronger
association with coronary heart disease among
women than among men. No sex differences were
found for the association of C reactive protein with
coronary heart disease. The exercise meta-analysis
was restricted to women and the depression meta-ana-
lysis did not report effects separately in women and
men.
Confounding—Adjustments for a priori confounders
of smoking, bloodpressure, and cholesterol concentra-
tion were found in four of 22 aetiologic studies for
depression and coronary heart disease and one of
three studies for physical activity. Adjustments in the
C reactive protein studies (20/22) and diabetes studies
(26/37) were generally more consistent and complete,
although beyond smoking it was unclear which vari-
ables were included inmultivariate analyses. For aetio-
logical meta-analyses of the four risk markers, the
effect on coronary heart disease was apparent after
multivariable adjustments. Reporting of unadjusted
or age adjusted and multivariate adjusted results was
inconsistent.
Biases—Statistical heterogeneity, present in all the
meta-analyses, was partly attributable to differences
in measurement of exposure for depression and physi-
cal activity, and year of publication for C reactive pro-
tein. Depression was defined by 12 different methods,
RESEARCH
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but relatively standardised methods were used for
measurement of C reactive protein concentration and
diabetes. For depression, but not for C reactive protein
or diabetes, stronger effectswere observedwith shorter
follow-up. Adjustment for severity of coronary heart
disease in prognostic studies reduced the relative risk
for depression by 45%. Evidence of small study bias
(often indicative of publication bias or a strong associa-
tion betweenmethodological weakness and a non-null
association in the expected direction in smaller studies
compared with larger studies) was present for depres-
sion but absent for physical activity, diabetes, and C
reactive protein.
Other meta-analyses of observational studies—The find-
ings of the meta-analyses of observational studies
included in our analysis were consistent with results
of other eligible meta-analyses on this subject (see
web extra appendix). For depression, adjusted relative
risks rangedbetween1.5 (1.4 to 1.6) and 1.9 (1.5 to 2.4).
Similarly, a consistently strong association was found
between diabetes and the incidence andmortality after
coronary heart disease, with stronger relations identi-
fied forwomen than formen. Exercisewas consistently
protective for coronary heart disease, ranging from 0.5
(0.5 to 0.6) to 0.8 (0.6 to 1.2). Othermeta-analyses con-
firmed the increased risk for coronary heart disease for
people in the highest third of C reactive protein con-
centrations.
Genetic evidence
Table 2 summarises the results of our search for meta-
analyses of genetic variants, indexing differences in the
risk markers of interest. Meta-analyses for two genetic
variants were identified, which have been investigated
in relation to both depression and coronary heart dis-
ease: MTHFR12 and APOE.13 14 The MTHFR variant
was positively associatedwithboth depression and cor-
onary heart disease, whereas the ε2 APOE genotype
was linked to a reduced risk of depression and of cor-
onaryheart disease.12 15w4No replicated genetic variant
for physical activity was identified that could be
assessed in relation to coronary heart disease.We iden-
tified two syntheses of a genetic variant in the CRP
gene in which the expected relation for coronary
heart disease events under a causal model, in the light
of its effect on C reactive protein levels, was not
observed.16w2 Despite the large number of meta-ana-
lyses showing genes associated with diabetes, none
examined the association of these variants with coron-
ary heart disease.
Randomised controlled trials
We identified four randomised controlled trials of dif-
ferent interventions for the treatment of depression
among patients with coronary heart disease (table 3).
None of these trials showed a beneficial effect on death
or cardiovascular events.w5-w8 No randomised con-
trolled trials were identified on the effect of treating
depression in healthy populations (or on the effect of
prevention of depression) in relation to risk of coron-
ary heart disease. No randomised controlled trials
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were found of interventions that specifically increased
physical activity (in isolation from, for example,
improvements in diet, or compliance with drugs) in
healthy populations, whereas exercise based rehabili-
tation reduced the risk of mortality among people with
coronary heart disease (0.7, 0.6 to 1.0).w9 Currently
there are no interventions that specifically lower C
reactive protein levels, and hence no randomised con-
trolled trials that could test the causal importance of C
reactive protein in coronary heart disease. Rando-
mised controlled trials (fourmeta-analyses and 70 indi-
vidual trials) of different hypoglycaemic agents in
patients with diabetes without or with manifest coron-
ary heart disease provided some, but not consistent,
support that lowering glucose concentrations reduced
the rate of coronary heart disease events.w17-w21
Guidelines
Neither the Scottish Intercollegiate Guideline Net-
work nor the European guidelines adopted an explicit
method for displaying and comparing evidence across
risk markers (table 4). The Scottish but not European
guidelines reported a level of evidence for some state-
ments. Both guidelines made clear, albeit differing,
statements on the importance of depression in the
onset and progression of coronary heart disease.
Neither the only randomised trial with statistical
power to detect differences in event rates
(ENRICHD)w5 nor theCochranemeta-analysis of psy-
chological interventions17 was cited in the executive
summary of the European guidelines. Post hoc sub-
group analyses were cited.18 The Scottish guidelines
cited neither trials normeta-analyses but did cite a pre-
vious position statement, which itself cites only an
older narrative systematic review. Neither guideline
suggested that C reactive protein was an important
risk marker: for the Scottish guidelines it was neither
mentioned nor any rationale given as to why not.
Observational studies and Mendelian randomisation
studies were cited for the European guidelines meta-
analyses, and the association was stated as “often ser-
iously confounded.”
DISCUSSION
The horizontal systematic review is a new method to
compare the evidence on diverse riskmarkers in a uni-
fied explicit framework of the largest available synth-
eses of the most important forms of evidence. This
approach highlighted differences and deficiencies in
the evidence of causal relevance across the four
selected risk markers: psychosocial, behavioural, bio-
marker, and metabolic disease. The evidence that
depression, low physical activity, or C reactive protein
concentration causes coronary heart disease seems less
strong than that for diabetes. Randomised trials of spe-
cific interventions are lacking for C reactive protein
and null for depression, and although they support
the role of exercise in the secondary prevention of cor-
onary heart disease they are not available to test the
causal hypothesis. Neither the European nor Scottish
guidelines gave explicit criteria for assessing evidence
to enable prioritisation of the impact of individual risk
markers. However the emphasis given to the causal
Table 2 | Genetic variants (single nucleotide polymorphisms, SNPs) associated with risk marker (depression, exercise, C reactive protein, and diabetes) and
coronary heart disease in healthy populations
Variable
MTHFR C677T
(TT v CC) rs1801133
APOE carriers
(ε2 v ε3/3) No SNPs
CRP T1444C rs1130864
(TT v any C)
8 SNPs identified
in recent review*
Outcomes Depression Coronary heart
disease
Depression ε2 v
ε3 allele
Coronary heart
disease ε2
carriers v ε3/3
Exercise C reactive
protein
Coronary heart
disease
Type 2 diabetes Coronary heart
disease
SNP identified
from genome
wide scans
No No No No — No No Yes Not same as for
type 2 diabetes
Largest
meta-analysis
Gilbody2007w15 Lewis 2005w4 Lopez-Leon
2008w1
Bennett
2007w16
— Lawlor 2008w2 Lawlor 2008w2 Jafar-
Mohammadi
2008w3
—
No of outcome
events
1280 26 000 827 21 331 — NA 4610 >6700 —
No of studies in
meta-analysis
10 80 7 17 — 5 5 5 reports (each
with multiple
replication
studies)
—
Unadjusted
relative risk
(95% CI)
1.36
(1.11 to 1.67)
1.14
(1.05 to 1.24)
0.51
(0.39 to 0.68)
0.80
(0.70 to 0.90)
1.21
(1.09 to 1.43)
(geometric
weighted mean
difference)
1.01
(0.74 to 1.38)†
Range
1.12-1.37
—
Instrumental
variable test*
NA NA NA NA — Null finding
(underpowered)
Null finding
(underpowered)
NA NA
NA=not available.
*Testing whether risk marker is associated with coronary heart disease to extent it is associated with genetic variant—that is, exploiting part of phenotypic variation which is not related to
potential confounding markers. A positive finding supports causality whereas a null finding suggests that observed association between risk marker and coronary heart disease may be
confounded or due to reverse causality.
†Adjusted estimate.
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and clinical relevance of depression in the guidelines
was inconsistent with the available evidence.
Closing the translational gap
Discordance exists between the large number of mar-
kers that are associated with coronary heart disease3
and the small number of targets for intervention. This
highlights the need for our approach, which aims to
prioritise targets. Our approach is horizontal in two
senses: a comparisonwasmade across diversemarkers
and a comparison was made across different forms of
evidence. We selected four risk markers as examples;
the approach is scaleable to all risk markers.
Three complementary designs for obtaining causal
evidence
Associations between putative riskmarkers and coron-
ary heart disease are easy to show in observational stu-
dies but may be confounded, as has been shown by
negative trials of hormone replacement therapy and
vitamins on coronary heart disease.19 We marshalled
three approaches, which aimed, with varying limita-
tions, to mimic the ideal, unconfounded experiment;
prospective observational studies (multivariate adjust-
ment for confounders), genetic studies (which utilise
genetic variants that influence themodifiable exposure
and that are assigned at random and can therefore be
used as an instrument for the unconfounded and
unbiased associationof the genetic variantwith the out-
come of interest), and randomised trials (where the
investigator influences exposure). Low density lipo-
protein cholesterol provides an example with conver-
ging evidence from all these approaches: robust
associations between high concentrations of low den-
sity lipoprotein cholesterol and coronary heart disease
shown in observational cohort studies20; genetic var-
iants that relate to lower concentrations of low density
lipoprotein cholesterol (for example, in PCSK9,21 the
APOE,22 and LDL receptor gene)23 also found to be
associated with a reduced risk of coronary heart dis-
ease; and trials on low density lipoprotein cholesterol
lowering confirmed the protection against coronary
heart disease.24 We excluded study designs that may
be associated with lower validity, such as individual
observational studies that have not (yet) been synthe-
sised, non-randomised trials, and studies on biological
mechanisms. Such studies have been the basis for
guideline recommendations.25 We included the forms
of large scale evidence, which aims to evaluate the cau-
sal hypothesis, with a low tolerance for false positive
findings. Our approach could be extended to incorpo-
rate small scale experimental studies in humans (as part
of a “teleoanalysis” approach)26 and, with due
caveats,27 experimental studies in animals. Such exten-
sions to other forms of evidence should acknowledge
that studies in the discovery phase have a higher toler-
ance for false positive findings, as the aim is not to
abandon a potentially important risk marker
prematurely.28
Observational evidence
Risk markers were associated with relative risks from
1.5 (C reactive protein) to over 3 (diabetes), but adjust-
ment for established risk factors of smoking, blood
pressure, and cholesterol concentration was least com-
mon among studies of depression and exercise. These
psychosocial (depression) and behavioural (exercise)
factors were also more prone to information biases,
withmultiple instruments used to determine exposure.
There was evidence of reverse causality and publica-
tion bias for depression.We found nometa-analyses in
a prognostic setting of C reactive protein or exercise.
Given that the guidelines make recommendations in
secondary prevention and since aetiological markers
may not necessarily be prognostic, this lack of synthe-
sised evidence is important. Thus, for example, meta-
analyses of body mass index in the prognosis of
patients with coronary disease suggest no adverse
effect for obesity,29 whereas those for aetiological asso-
ciations show an increased risk.30
Genetic evidence
Genetic studies using Mendelian randomisation have
been more frequently applied to assessing C reactive
protein31w2 than for our other three risk factors.Despite
being relatively underpowered, the emerging evidence
does not suggest an important role for C reactive pro-
tein in causing coronary heart disease. A new and large
collaboration should provide a more definitive answer
in the near future.32 For depression, exercise, and dia-
betes, evidence from Mendelian randomisation for
their causal role in risk of coronary heart disease was
limited. The robust positive associations of MTHFR
with both depression and coronary heart disease
could indicate a causal effect of depressionon coronary
heart disease but is more likely to reflect folate intake
andmetabolism as a causal marker for both outcomes.
The emergence of whole genome association studies
and complete genome sequencing is improving our
understanding of the genomic architecture underlying
complex traits. Mendelian randomisation may offer a
powerful tool to understand causality, particularly for
risk marker traits that are controlled by a limited num-
ber of genetic variants of relatively strong effect.
Randomised controlled trials
Successful treatment of depression in patients with
established coronary heart disease in randomised con-
trolled trials does not show benefits in subsequent
death or rates of coronary heart disease events. This
provides no support for the causal hypothesis that
avoiding depression is important in the secondary pre-
vention of coronary heart disease, but it is a matter of
debatewhether it provides evidence against. For exam-
ple, it might be argued that it is the intervention rather
than the hypothesis that is wrong. Trials were lacking
for the effect of C reactive protein concentration or
physical activity among healthy populations, whereas
there was evidence that glucose control may provide
some reduction in coronary heart disease events. Inter-
pretation was difficult in the situation of trials with
RESEARCH
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pleiotropic effects; for instance, the evidence that exer-
cise in combinationwith other aspects of rehabilitation
reduced the risk of death amongpatientswith coronary
heart disease.w9 A new specific C reactive protein inhi-
bitor drug is being used to determine the functions of C
reactive protein in the experimental setting and will be
tested in the settingof acute coronary events.However,
the lack of oral bioavailability and short half life cur-
rently precludes its use in long termprevention trials in
humans.33 Randomised controlled trials of lipid lower-
ing statins are a non-specific test of the role of
C reactive protein and coronary heart disease, because
of the major effect on low density lipoprotein
concentrations.34 It has been shown that false findings
from observational studies continue to be influential,
despite being contradicted by randomised trial
evidence.35 Null randomised trials have led to revi-
sions in the causal and mechanistic hypotheses—for
example, the finding that positive inotropic agents do
not prolong life in heart failure, refocused attention
away from a mainly haemodynamic model of heart
failure.36
Clinical implications and consistency of the guidelines
By using horizontal systematic reviews, clinicians,
guideline developers, funders of research, public
health policy makers, and journal editors and their
peer reviewers might be aided in making more consis-
tent and less biased decisions. The graphical summary
of evidence may serve a practical purpose in guideline
groups, facilitating more explicit debate of the impor-
tance of riskmarkers across the multiple fields of inter-
est of contributors. The two most recent guidelines on
primary prevention of cardiovascular disease refer to a
wide “penumbra” of risk markers beyond smoking,
blood pressure, and cholesterol concentration; over
50 markers in the most recent European guidelines.1
The guidelines cite more than 1100 references (joint
societies) and 315 references (Scottish Intercollegiate
Guideline Network) but do not provide a systematic
comparison of the quality or strength of evidence
across the risk markers that were included. There was
inconsistency in the conclusions reached by the two
guidelines across the four risk markers that we evalu-
ated. For instance, C reactive protein was not consid-
ered by the Scottish Intercollegiate Guideline
Network. Depression was accorded higher promi-
nence in the European guidelines than in the Scottish
guidelines and within the European guidelines was
accorded higher prominence than C reactive protein,
which is not consistent with the evidence in the hori-
zontal systematic review. Depression is worth treating
in its own right, irrespective of any causal relation with
coronary heart disease; but the same is true for other
conditions, such as chronic obstructive airways dis-
ease, which are not mentioned in the guidelines.
Limitations of this horizontal systematic review
There are important limitations in this initial illustra-
tion of a horizontal systematic review. Firstly, the
method depends on the availability and quality ofTa
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large scale syntheses of evidence. These aremore com-
monly available for blood based markers than for
behavioural or psychosocial markers; horizontal sys-
tematic reviews may stimulate research groups to
raise or defend the profile of research in their subdisci-
plines. A range of measures of effect were included in
the reviews, and where the confidence intervals for the
effect estimates werewide this precluded reaching firm
conclusions. Increasing use of horizontal systematic
reviews may provide an impetus to improving the
number and quality of meta-analyses, particularly
those using individual participant data. Secondly, the
horizontal systematic review is narrative, without
novel methods for data analysis, offering no explicit
ranking of causal relevance nor attempting to posit a
decision threshold above which a marker might be
considered causal.
Research implications and need for unbiased field
synopses
Further research is required to develop the method of
horizontal systematic review. Firstly, methods could
be developed to derive relative weights of evidence
building on the judgments of groups of experts,37 Baye-
sian methods could be used for the synthesis of evi-
dence, or models could be developed to combine
features from different studies to derive quantitative
estimates.38 Secondly, extension is required to the
whole range of risk markers that are included in guide-
lines, thus providing a systematic synopsis of the speci-
alty. Thirdly, extension to other chronic diseases
should be explored—for example, in the specialty of
cancer, horizontal systematic reviews could build on
the assessment of causality used by the International
Agency for Research on Cancer. Fourthly, horizontal
systematic reviews should be regularly updated as evi-
dence changes to minimise the lag time between the
generation of evidence and the development of guide-
lines and could take advantage of continually updated
databases of genetic studies in this process. The
conclusions of our review are not altered if the publica-
tion year of evidence is truncated two years before the
publication of guidelines—that is, 2005. Fifthly, there
are important considerations beyond causal relevance
when developing guidelines, such as economic consid-
erations and the additional deleterious effects of the
risk markers (for example, the impact of depression
on quality of life), and the framework could be
extended to encompass these considerations. Sixthly,
it should be noted that non-causal markers can be used
in risk prediction (for example, socioeconomic posi-
tion) and this requires distinct consideration in the
observational evidence.
Conclusion
Horizontal systematic review in which the causal rele-
vanceof diverse riskmarkers is compared in an explicit
framework helps clarify the relative standing of each
risk marker. Field synopses, expanded to include the
whole range of risk markers considered of potential
clinical or public health relevance, should be devel-
oped to prioritise research efforts and to focus recom-
mendations on those markers most likely to be causal.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Diverse psychosocial, behavioural, and biological markers are claimed to be independently
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